ANIX Pengajuan SEC - Anixa Biosciences, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300PW2C2QTAJL2D19
CIK	715446

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Anixa Biosciences, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

May 28, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN
March 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 ANIXA BIOS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com
March 21, 2025	EX-99.1	EX-99.1 Exhibit 99.1
March 11, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,
February 6, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.
January 10, 2025	EX-FILING FEES	Calculation of Filing Fee Table. (Filed herewith.) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Anixa Biosciences, Inc.
January 10, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E
January 10, 2025	EX-14	Code of Conduct (Filed herewith.) Exhibit 14 Anixa Biosciences, Inc. Code Of Business Conduct And Ethics As Initially Approved by the Board of Directors January 17, 2018 This Code of Business Conduct and Ethics covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide the Company’s and its subsidiaries’ employees (collectively, “Covered Persons
January 10, 2025	S-8	As filed with the Securities and Exchange Commission on January 10, 2025 As filed with the Securities and Exchange Commission on January 10, 2025 Registration No.
November 8, 2024	EX-99.1	Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting Exhibit 99.1 Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting ● Data continues positive trend as additional patients are enrolled in 3 cohorts ● Vaccine was safe and well tolerated by participants in all 3 cohorts ● Protocol defined immune responses were exhibit
November 8, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C
November 8, 2024	EX-99.2	EX-99.2 Exhibit 99.2
September 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC
June 4, 2024	EX-10.1	Joint Development and Option Agreement, dated May 3, 2024, between the Company and The Cleveland Clinic Foundation. (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “***” Joint Development and Option Agreement Preamble This Joint Development and Option Agreement (“JDA’’), effective and binding as of the last date of execution herein (“EFFECTIVE DATE”), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its AFFILIATEs as “CCF”), an Ohio non-profit co
June 4, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN
May 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 ANIXA BIOSCIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Commis
May 8, 2024	EX-99.1	Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines – Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines – Exhibit 99.1 Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines – Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines – SAN JOSE, Calif., May 8, 2024 /PRNewswire/ - Anixa Biosciences, Inc. (“Anixa” or the
May 3, 2024	SC 13D	ANIX / Anixa Biosciences, Inc. / Catelani Michael Activist Investment SC 13D 1 formsc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CUSIP Number) Michael Catelani c/o Anixa Biosciences, Inc. 3150 Almaden Expressway, Suite 250 San Jose, CA 95
March 22, 2024	EX-99.1	EX-99.1 Exhibit 99.1
March 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 ANIXA BIOS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com
March 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,
February 8, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.
January 16, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E
January 16, 2024	S-8	As filed with the Securities and Exchange Commission on January 16, 2024 As filed with the Securities and Exchange Commission on January 16, 2024 Registration No.
January 16, 2024	EX-10.10	Amendment to Exclusive License Agreement between the Company and The Cleveland Clinic Foundation. (Filed herewith.) EX-10.10 2 ex10-10.htm Exhibit 10.10
January 16, 2024	EX-99.1	Clawback Policy (Filed herewith.) Exhibit 99.1 ANIXA BIOSCIENCES, INC. EXECUTIVE COMPENSATION CLAWBACK POLICY Adopted as of November 17, 2023 The Board of Directors (the “Board”) of Anixa Biosciences, Inc. (the “Company”) has adopted the following executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company or included in
January 16, 2024	EX-19	Insider Trading Policy (Filed herewith.) Exhibit 19 Anixa Biosciences, Inc. POLICY ON INSIDER TRADING Anixa Biosciences, Inc., a Delaware corporation (the “Company”), is committed to the highest standards of ethical business conduct. This Insider Trading Policy provides the standards of the Company on trading and causing the trading of the Company’s securities or securities of other publicly-traded companies while in possession of confid
January 16, 2024	SC 13D/A	ANIX / Anixa Biosciences, Inc. / KUMAR AMIT Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CU
January 16, 2024	EX-FILING FEES	Calculation of Filing Fee Table. (Filed herewith.) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Anixa Biosciences, Inc.
December 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 ANIXA BI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C
December 7, 2023	EX-99.1	Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, inc Exhibit 99.1 Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – –
December 7, 2023	EX-99.2	EX-99.2 Exhibit 99.2
September 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC
June 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN
April 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 ANIXA BIOS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com
April 17, 2023	EX-99.1	Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine Immune responses were observed at all dose levels Exhibit 99.1 Anixa Biosciences, Inc. 3150 Almaden Expressway Suite 250 San Jose, CA 95118 408.708.9808 NASDAQ: ANIX Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine Immune responses were observed at all dose levels SAN JOSE, Calif., April 17, 2023 - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and pr
April 17, 2023	EX-99.2	EX-99.2 Exhibit 99.2
March 17, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ANIXA BIOSC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Comm
March 10, 2023	EX-99.1	EX-99.1 Exhibit 99.1
January 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.
January 4, 2023	S-8	As filed with the Securities and Exchange Commission on January 4, 2023 As filed with the Securities and Exchange Commission on January 4, 2023 Registration No.
January 4, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E
January 4, 2023	EX-FILING FEES	Calculation of Filing Fee Table. (Filed herewith.) Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Anixa Biosciences, Inc.
December 8, 2022	EX-99.2	EX-99.2 Exhibit 99.2
December 8, 2022	EX-99.1	Press Release Exhibit 99.1
December 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 ANIXA BI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C
September 29, 2022	EX-99.1	EX-99.1 Exhibit 99.1
September 29, 2022	8-K	Financial Statements and Exhibits, Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation)
September 15, 2022	CORRESP	ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 September 15, 2022 CORRESP 1 filename1.htm ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 September 15, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Tyler Howes Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed September 9, 2022, as amended File No. 333-267
September 12, 2022	DEL AM	September 12, 2022 September 12, 2022 By EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7010 Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 (File No. 333-267369) Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (File No. 333-267369) filed by Anixa Biosciences, Inc. on September 9, 2022 (the ?Registration Statement?). Pursuant to Rul
September 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC
September 9, 2022	S-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Anixa Biosciences, Inc. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on September 9, 2022 Registration No.
September 9, 2022	EX-FILING FEES	Calculation of Filing Fee Table* Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Anixa Biosciences, Inc.
September 9, 2022	EX-10.1	Amendment No. 1 to Exclusive License Agreement between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended July 31, 2022.) (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.1 Redactions with respect to certain portions hereof denoted with ?***? AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT BETWEEN THE CLEVELAND CLINIC FOUNDATION AND ANIXA BIOSCIENCES, INC. This Amendment No. 1 to Exclusive License Agreement (this ?Amendment?), is made and entered into effective as of June 1, 2022 (the ?Amendment Date?), by and between The Cleveland Clinic Foundation (?CCF
September 9, 2022	EX-4.5	Form of Indenture* Exhibit 4.5 ANIXA BIOSCIENCES, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Seri
September 9, 2022	EX-10.1	Form of Controlled Equity OfferingSM Sales Agreement (Incorporated by reference to Exhibit 10.1 to our Form S-3 dated September 9, 2022) Exhibit 10.1 ANIXA BIOSCIENCES, INC. Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales Agreement [?], 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Anixa Biosciences, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issuance a
August 17, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Co
June 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, IN
April 15, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com
March 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES,
March 11, 2022	EX-99.1	Corporate Presentation Exhibit 99.1
March 11, 2022	8-K	Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com
January 28, 2022	DEF 14A	Schedule 14A DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ C
January 4, 2022	S-8	As filed with the Securities and Exchange Commission on January 4, 2022 As filed with the Securities and Exchange Commission on January 4, 2022 Registration No.
January 4, 2022	EX-10.8	Amended and Restated Master Collaboration Agreement, dated November 1, 2021, between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Incorporated by reference to Exhibit 10.8 to our Form 10-K for the fiscal year ended October 31, 2021.) Exhibit 10.8
January 4, 2022	EX-4.2	Form of Warrant issued to Acorn Management Partners LLC. (Filed herewith.) Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES issuable upon exercise hereof HAS BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR ANY STATE SECURITIES OR ?BLUE SKY LAWS,? AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SU
January 4, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC. (E
December 9, 2021	8-K	Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C
October 28, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C
October 4, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Co
September 3, 2021	SC 13D/A	ANIX / Anixa Biosciences Inc / KUMAR AMIT Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CU
September 1, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-37492 ANIXA BIOSCIENCES, INC
June 16, 2021	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Comm
June 10, 2021	EX-10.1	Assignment Agreement dated May 1, 2021, between the Company, OntoChem GmbH and MolGenie GmbH. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended April 30, 2021.) Exhibit 10.1 Assignment Agreement This Assignment Agreement (?ASSIGNMENT?) is entered into as of April 30, 2021, (?Effective Date?) by and between OntoChem GmbH, a German limited liability company registered at the courts of Stendal whose address is Bl?cherstrasse 24, 06120 Halle (Saale), Germany (?ASSIGNOR?), MolGenie GmbH, a German limited liability company registered at the Courts of Stuttgart
June 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 Commission file number 001-37492 A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc
June 10, 2021	SC 13D/A	ANIX / Anixa Biosciences Inc / KUMAR AMIT Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CUSIP Number) Amit Kumar c/o
June 10, 2021	EX-10.2	Amendment 2 to the Collaboration Agreement between the Company and MolGenie GmbH. (Incorporated by reference to Exhibit 10.2 to our Form 10-Q for the fiscal quarter ended April 30, 2021.) (Certain information has been redacted in the marked portions of the exhibit.) Redactions with respect to certain portions hereof denoted with ?***? Exhibit 10.2 AMENDMENT NO. 2 TO COLLABORATION AGREEMENT This AMENDMENT NO. 2 TO COLLABORATION AGREEMENT (the ?Amendment?) is made as of May 1, 2021 (the ?Amendment Effective Date?), by and between Anixa Biosciences, Inc., a Delaware corporation (?Anixa?), and MolGenie GmbH, a German limited liability company (?MolGenie?). Anixa
May 27, 2021	EX-99.1	Corporate Presentation Exhibit 99.1
May 27, 2021	8-K	Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Commi
April 9, 2021	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) [X] Definitive Proxy Statement [ ] Definitive Additional Materials [ ] Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.
April 2, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com
April 2, 2021	EX-3.1	Amendment to the Amended and Restated Bylaws of the Company. (Incorporated by reference to our Form 8-K, dated April 2, 2021.) Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF Anixa Biosciences, Inc. (a Delaware corporation) March 29, 2021 This Amendment (the ?Amendment?) to the Amended and Restated Bylaws (the ?Bylaws?) of Anixa Biosciences, Inc., a Delaware corporation (the ?Corporation?), hereby amends the Bylaws currently in effect as follows: 1. A new Section 11.3 is hereby added to Article 11 as follows:
March 30, 2021	PRE 14A	- PRE 14A 1 pre14-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement
March 24, 2021	424B5	4,285,715 Shares of Common Stock Underwriter Warrants to Purchase 300,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-232067 PROSPECTUS SUPPLEMENT (To prospectus dated June 21, 2019) 4,285,715 Shares of Common Stock Underwriter Warrants to Purchase 300,000 Shares of Common Stock We are offering 4,285,715 shares of common stock. In addition, in connection with the offering, we are issuing common stock purchase warrants to the underwriter. These warran
March 24, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (Com
March 24, 2021	EX-1.1	Amended and Restated Underwriting Agreement, dated March 22, 2021, between Anixa Biosciences, Inc. and H.C. Wainwright & Co., LLC. Exhibit 1.1 4,285,715 SHARES of Common Stock ANIXA BIOSCIENCES, INC. AMENDED AND RESTATED UNDERWRITING AGREEMENT March 22, 2021 H.C. Wainwright & Co., LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: The undersigned, Anixa Biosciences, Inc., a company incorporated under the laws of Delaware (col
March 24, 2021	EX-4.1	Form of Underwriter Warrants. (Incorporated by reference to Exhibit 4.1 to our Form 8-K, dated March 24, 2021.) Exhibit 4.1 COMMON STOCK PURCHASE WARRANT ANIXA BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: March 25, 2021 Issue Date: March 25, 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
March 23, 2021	FWP	Free Writing Prospectus Filed pursuant to Rule 433 of the Securities Act of 1933, as amended Registration No.
March 22, 2021	FWP	Free Writing Prospectus Filed pursuant to Rule 433 of the Securities Act of 1933, as amended Registration No.
March 22, 2021	424B5	Subject to Completion, Dated March 22, 2021 Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-232067 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell nor do they seek an offer to buy these securities in any jurisdiction where the offer or sale is
March 11, 2021	EX-10.2	Joint Development and Option Agreement, dated January 26, 2021, between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.2 to our Form 10-Q for the fiscal quarter ended January 31, 2021.) (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.2 Redactions with respect to certain portions hereof denoted with ?***? Joint Development and Option Agreement Preamble This Joint Development and Option Agreement (?JDA?), effective and binding as of the last date of execution herein (?EFFECTIVE DATE?), is by and between The Cleveland Clinic Foundation (hereinafter referred to along with its AFFILIATEs as ?CCF?), an Ohio non-profit cor
March 11, 2021	EX-10.1	Amendment to License Agreement between Certainty Therapeutics, Inc. and The Wistar Institute of Anatomy and Biology. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended January 31, 2021.) (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.1 Redactions with respect to certain portions hereof denoted with ?***? AMENDMENT OF LICENSE AGREEMENT This Amendment of License Agreement (this ?Amendment?) is made as of January 22, 2021 (the ?Amendment Effective Date?), by and between The Wistar Institute of Anatomy and Biology, a nonprofit corporation organized and existing under the laws of the Commonwealth of Pennsylvania located
March 11, 2021	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of incorporation or o
February 5, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1) A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109 (CUSIP Number) Lewis H. Titte
January 28, 2021	8-K	Entry into a Material Definitive Agreement - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (C
January 7, 2021	EX-4.2	Form of Warrant issued to Acorn Management Partners LLC. (Filed herewith.). Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES issuable upon exercise hereof HAS BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES OR “BLUE SKY LAWS,” AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SU
January 7, 2021	EX-10.14	Exclusive License Agreement, dated October 20, 2020, between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.14 to our Form 10-K, for the fiscal year ended October 31, 2020.) (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.14 Redactions with respect to certain portions hereof denoted with “*” EXCLUSIVE LICENSE AGREEMENT between THE CLEVELAND CLINIC FOUNDATION and ANIXA BIOSCIENCES, INC. dated as of October 20, 2020 Redactions with respect to certain portions hereof denoted with “*” EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this “Agreement”) is made and entered into effective as of
January 7, 2021	EX-10.13	Amendment to Collaboration Agreement between the Company and OntoChem GmbH. (Incorporated by reference to Exhibit 10.13 to our Form 10-K, for the fiscal year ended October 31, 2020.) Exhibit 10.13 AMENDMENT TO COLLABORATION AGREEMENT This AMENDMENT TO COLLABORATION AGREEMENT (the “Amendment”) is made as of October 19, 2020 (the “Amendment Effective Date”), by and between Anixa Biosciences, Inc., a Delaware corporation (“Anixa”), and OntoChem GmbH, a German limited liability company (“OntoChem”). Anixa and OntoChem are referred to herein individually as a “Party” and collective
January 7, 2021	S-8	- As filed with the Securities and Exchange Commission on January 7, 2021 Registration No.
January 7, 2021	EX-21	Subsidiaries of Anixa Biosciences, Inc. (Incorporated by reference to Exhibit 21 to our Form 10-K, for the fiscal year ended October 31, 2020.) Exhibit 21 SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands CopyTele Marketing Inc. British Virgin Islands ITUS Patent Acquisition Corporation State of Delaware J-Channel Industries Corporation
January 7, 2021	EX-10.10	Amendment 2 to the Collaboration Agreement between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Filed herewith.) (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.10 Redactions with respect to certain portions hereof denoted with “***” AMENDMENT 2 TO THE COLLABORATION AGREEMENT BETWEEN CERTAINTY THERAPEUTICS, INC. AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. Moffitt Agreement Identifier: Anixa-CERTainty Contract (Conejo-Garcia) 17-0173 Project Title: Development of CAR-T/CER-T Therapies for Ovarian and Prostate Cancer Moffitt Pri
January 7, 2021	10-K	Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37492 ANIXA BIOSCIENCES, INC
January 7, 2021	EX-14	Code of Conduct (Incorporated by reference to Exhibit 14 to our Form 10-K, for the fiscal year ended October 31, 2020.) Exhibit 14 Anixa Biosciences, Inc. Code Of Business Conduct And Ethics As Approved by the Board of Directors January 17, 2018 This Code of Business Conduct and Ethics covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide the Company’s principal executive officer, principal financial officer, principal accou
December 1, 2020	8-K	Entry into a Material Definitive Agreement - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation) (
September 16, 2020	EX-99.1	Corporate Presentation Exhibit 99.1
September 16, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-37492 11-2622630 (State or other jurisdiction of incorporation)
September 8, 2020	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of incorporation or orga
August 17, 2020	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
August 17, 2020	EX-3.1	Certificate of Amendment to the Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to our Form 8-K, dated August 13, 2020.) Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ANIXA BIOSCIENCES, INC. The undersigned, for the purposes of amending the Certificate of Incorporation of Anixa Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The Board of
August 17, 2020	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Co
July 20, 2020	DEFA14A	- DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
July 2, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR SECTION 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commi
July 2, 2020	DEF 14A	- DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.
July 2, 2020	EX-99.1	Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Expanding Therapeutics Portfolio Exhibit 99.1 Anixa Announces Strategic Program Realignment Focused on Advancement of its Therapeutic and Vaccine Pipeline Focusing Resources on Existing Breast Cancer Vaccine, CAR-T Therapy and Covid-19 discovery Technologies and Expanding Therapeutics Portfolio SAN JOSE, Calif., July 2, 2020 /PRNewswire/- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and
June 22, 2020	PRE 14A	- PRELIMINARY PROXY STATEMENT PRE 14A 1 pre14a.htm PRELIMINARY PROXY STATEMENT SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a
June 9, 2020	EX-10.1	Collaboration Agreement, dated April 14, 2020, between the Company and OntoChem GmbH. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended April 30, 2020.) (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “***” COLLABORATION AGREEMENT This Collaboration Agreement (the “Agreement”) is made as of April 14th, 2020 (the “Effective Date”) by and between Anixa Biosciences, Inc., a Delaware corporation, located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, U.S.A. (“Anixa”), and OntoChem GmbH, a German limited liabili
June 9, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incor
April 20, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2020 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com
March 9, 2020	10-Q	ANIX / Anixa Biosciences Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc
January 10, 2020	10-K/A	ANIX / Anixa Biosciences Inc 10-K/A - Annual Report - FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment No. 1) [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ANIXA
January 9, 2020	EX-21	Subsidiaries of Anixa Biosciences, Inc. (Incorporated by reference to Exhibit 21 to our Form 10-K, dated January 9, 2020) Exhibit 21 SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands CopyTele Marketing Inc. British Virgin Islands ITUS Patent Acquisition Corporation State of Delaware J-Channel Industries Corporation
January 9, 2020	424B3	Prospectus Supplement No. 1 to Reoffer Prospectus Anixa Biosciences, Inc. Up to 7,030,112 Shares of Common Stock under the 2018 Share Incentive Plan, Employee Stock Purchase Plan, 2010 Share Incentive Plan, as amended, certain Non-Plan Time Based Sto Filed Pursuant to Rule 424(b)(3) Registration No. 333- 227653 Prospectus Supplement No. 1 to Reoffer Prospectus of Anixa Biosciences, Inc. Up to 7,030,112 Shares of Common Stock under the 2018 Share Incentive Plan, Employee Stock Purchase Plan, 2010 Share Incentive Plan, as amended, certain Non-Plan Time Based Stock Option Agreements and certain Non-Plan Performance Based Stock Option Agreements T
January 9, 2020	10-K	ANIX / Anixa Biosciences Inc 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ANIXA BIOSCIENCES, INC.
January 9, 2020	EX-3.8	Amended and Restated By-laws. (Incorporated by reference to Exhibit 3.8 to our Form 10-K for the fiscal year ended October 31, 2019.) Exhibit 3.8 AMENDED AND RESTATED BYLAWS OF ANIXA BIOSCIENCES, INC. (a Delaware Corporation) (Adopted Effective as of January 6, 2020) These Amended and Restated Bylaws of Anixa Biosciences, Inc., a Delaware corporation (the “Corporation”), are adopted pursuant to Article 12 of the Corporation’s existing Bylaws (the “Original Bylaws”) and are intended to amend, restate and replace, in their entiret
October 24, 2019	EX-99.1	1 EX-99.1 2 exhibit991.htm EXHIBIT 99.1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
October 24, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C
September 12, 2019	DEF 14A	ANIX / Anixa Biosciences Inc DEF 14A - - DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 Anixa Biosciences, Inc.
September 6, 2019	EX-10.1	Exclusive License Agreement, dated July 8, 2019, between the Company and The Cleveland Clinic Foundation. (Incorporated by reference to Exhibit 10.1 to our Form 10-Q for the fiscal quarter ended July 31, 2019.) (Certain information has been redacted in the marked portions of the exhibit.) Exhibit 10.1 Redactions with respect to certain portions hereof denoted with “*” EXCLUSIVE LICENSE AGREEMENT between THE CLEVELAND CLINIC FOUNDATION and ANIXA BIOSCIENCES, INC. dated as of July 8, 2019 Redactions with respect to certain portions hereof denoted with “*” EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this “Agreement”) is made and entered into effective as of July
September 6, 2019	10-Q	ANIX / Anixa Biosciences Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorp
September 6, 2019	EX-10.2	Amendment 1 to the Collaboration Agreement between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Incorporated by reference to Exhibit 10.2 to our Form 10-Q for the fiscal quarter ended July 31, 2019.) Exhibit 10.2 AMENDMENT 1 TO THE COLLABORATION AGREEMENT BETWEEN CERTAINTY THERAPEUTICS, INC. AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. Moffitt Agreement Identifier: Anixa-CERTainty Contract (Conejo-Garcia) 17-0173 Project Title: Development of CAR-T/CER-T Therapies for Ovarian and Prostate Cancer Moffitt Principle Investigator: Dr. Jose Conejo-Garcia The Agreement described abo
August 27, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdic
August 27, 2019	EX-99.1	IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE THOMAS S. HOWLAND, JR., derivatively on behalf of ANIXA BIOSCIENCES, INC. (f/k/a ITUS CORPORATION), Plaintiff, v. AMIT KUMAR, LEWIS H. TITTERTON, JR., ARNOLD M. BASKIES, JOHN MONAHAN, MICHAEL J. CATELANI, C.A. No.: 2018-0804-KSJM JOHN A. ROOP, ANTHONY CAMPISI, and DALE FOX, Defendants, and ANIXA BIOSCIENCES, INC. (f/k/a ITUS CORPORATION), Nominal D
August 21, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Co
August 21, 2019	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
July 18, 2019	8-K	Entry into a Material Definitive Agreement 8-K 1 form8k.htm FORM8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction
June 19, 2019	CORRESP	ANIX / Anixa Biosciences Inc CORRESP - - ANIXA BIOSCIENCES, INC. 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 June 19, 2019 VIA EDGAR U.S. Securities and Exchange Commission Office of Financial Services 100 F Street, N.E. Mail Stop 4628 Washington, DC 20549 Attn: Ronald Alper Re: Anixa Biosciences, Inc. Registration Statement on Form S-3 Filed June 11, 2019 File No. 333-232067 Dear Mr. Alper: Pursuant to Rule 461 under the Secur
June 12, 2019	10-Q	ANIX / Anixa Biosciences Inc 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incor
June 11, 2019	EX-10.1	At Market Issuance Sales Agreement, dated June 21, 2019, between the Company and B. Riley FBR, Inc. (Incorporated by reference to Exhibit 10.1 to our Registration Statement of Form S-3 filed June 11, 2019.) EX-10.1 4 exhibit101.htm EXHIBIT 10.1 Exhibit 10.1 ANIXA BIOSCIENCES, INC. Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement June [•], 2019 B. Riley FBR, Inc. 299 Park Avenue, 21st Floor New York, NY, 10171 Ladies and Gentlemen: Anixa Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley FBR, Inc. (the “Agent”)
June 11, 2019	EX-4.5	ANIXA BIOSCIENCES, INC., as [ ], as INDENTURE TRUSTEE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Exhibit 4.5 ANIXA BIOSCIENCES, INC., as ISSUER and [ ], as INDENTURE TRUSTEE INDENTURE Dated as of [ ] TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.01 Issuable in Seri
June 11, 2019	S-3	ANIX / Anixa Biosciences Inc S-3 - - FORM S-3 As filed with the Securities and Exchange Commission on June 11, 2019 Registration No.
May 23, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commi
May 23, 2019	EX-99.1	1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
March 13, 2019	10-Q	ANIX / Anixa Biosciences Inc FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc
January 25, 2019	8-K	Financial Statements and Exhibits, Other Events 8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2019 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdi
January 25, 2019	EX-99.1	Anixa Biosciences Conference Call Recording Available on Company Website Exhibit 99.1 Anixa Biosciences Conference Call Recording Available on Company Website SAN JOSE, Calif., January 25, 2019 /PRNewswire/ - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, today announced that it has made a recording of its January 24, 2019 conference call available on its website. The recording can be found on
January 11, 2019	EX-21	SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Isl Exhibit 21 SUBSIDIARIES OF ANIXA BIOSCIENCES, INC. Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands CopyTele Marketing Inc. British Virgin Islands ITUS Patent Acquisition Corporation State of Delaware J-Channel Industries Corporation
January 11, 2019	10-K	ANIX / Anixa Biosciences Inc FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ANIXA BIOSCIENCES, INC.
January 10, 2019	SC 13D/A	ANIX / Anixa Biosciences Inc / KUMAR AMIT - SCHEDULE 13D/A Activist Investment SC 13D/A 1 schedule13da.htm SCHEDULE 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3) ANIXA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 03528H109
October 2, 2018	S-8	Table of Contents As filed with the Securities and Exchange Commission on October 1, 2018 Registration No.
October 2, 2018	EX-4.14	Form of Stock Option Agreement (Incorporated by reference to Exhibit 4.14 of our Registration Statement on Form S-8 filed on October 1, 2018.) Exhibit 4.14 408.708.9808 NASDAQ: ITUS [Grant Date] [Employee] c/o ITUS Corporation 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 RE: Grant of Stock Option to Employee Dear [Employee]: On January 25, 2018, the Board of Directors of ITUS Corporation (the "Company") adopted the ITUS Corporation 2018 Share Incentive Plan (as the same was approved by the stockholders of the Company on March 29
October 2, 2018	EX-4.15	Form of Restricted Stock Award (Incorporated by reference to Exhibit 4.15 of our Registration Statement on Form S-8 filed on October 1, 2018.) Exhibit 4.15 ITUS CORPORATION 2018 SHARE INCENTIVE PLAN Award Agreement This Award Agreement evidences an Award of shares of Restricted Stock pursuant to the provisions of the ITUS Corporation 2018 Share Incentive Plan (the “Plan”) to the individual whose name appears below (the “Participant”), on the following express terms and conditions (capitalized terms not otherwise defined herein shall have
October 2, 2018	EX-4.13	2018 Share Incentive Plan. (Incorporated by reference to Exhibit 4.13 to our Form S-8 dated October 1, 2018.) Exhibit 4.13 ITUS CORPORATION 2018 SHARE INCENTIVE PLAN 1. Purpose. The ITUS Corporation 2018 Share Incentive Plan (the "Plan") is intended to provide incentives which will attract, retain and motivate highly competent persons as officers, employees and non-employee directors ("Director Participants"), of, and consultants to, ITUS Corporation (the "Company") and its subsidiaries and affiliates, by
October 2, 2018	EX-4.16	Employee Stock Purchase Plan (Incorporated by reference to Exhibit 4.16 of our Registration Statement on Form S-8 filed on October 1, 2018.) Exhibit 4.16 ITUS CORPORATION EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the ITUS Corporation Employee Stock Purchase Plan (the “Plan”), as adopted by the Board of Directors of the Company (the “Board”) and subsequently approved by the shareholders of the Company, is to encourage and facilitate the ownership of shares of common stock of the Company by eligible employees of the Company
October 1, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2018 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other juris
October 1, 2018	EX-3.1	Certificate of Amendment to the Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to our Form 8-K, dated October 1, 2018.) EX-3.1 2 exhibit31.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ITUS CORPORATION The undersigned, for the purposes of amending the Certificate of Incorporation of ITUS Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: FIRST: The B
October 1, 2018	EX-3.2	AMENDED AND RESTATED BYLAWS OF ANIXA BIOSCIENCES, INC. (a Delaware Corporation) (Adopted Effective as of October 1, 2018) Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ANIXA BIOSCIENCES, INC. (a Delaware Corporation) (Adopted Effective as of October 1, 2018) These Amended and Restated Bylaws of Anixa Biosciences, Inc., a Delaware corporation (formerly ITUS Corporation, the “Corporation”), are adopted pursuant to Article XIV of the Corporation’s existing Bylaws (the “Original Bylaws”) and are intended to amend, restate a
September 27, 2018	EX-99.1	EX-99.1
September 27, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commis
September 7, 2018	10-Q	ITUS / ITUS Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2018 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporation
August 17, 2018	DEF 14A	ITUS / ITUS Corp. DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 ITUS Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required.
July 27, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission
June 11, 2018	10-Q	ITUS / ITUS Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2018 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporatio
June 11, 2018	EX-3.1	Certificate of Amendment to the Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to our Form 10-Q for the fiscal quarter ended April 30, 2018.) Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ITUS CORPORATION The undersigned, for the purposes of amending the Certificate of Incorporation of ITUS Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: FIRST: The Board of Directors of the Corporatio
May 14, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission Fi
April 11, 2018	144	ITUS / ITUS Corp. FORM 144 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. OMB APPROVAL OMB Number: 3235-0101 Expires: June 30,
April 2, 2018	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission
March 27, 2018	EX-10.1	ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement March 27, 2018 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171 Exhibit 10.1 ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement March 27, 2018 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171 Ladies and Gentlemen: ITUS Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley FBR, Inc. (the “Agent”) as follows: 1. Issuance and Sale of Shares. The Compa
March 27, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission
March 27, 2018	424B5	ITUS CORPORATION Up to 2,200,000 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220963 Prospectus Supplement (To prospectus dated October 16, 2017) ITUS CORPORATION Up to 2,200,000 Shares of Common Stock We have entered into an At Market Issuance Sales Agreement with B. Riley FBR, Inc. (“B. Riley FBR”) relating to the sale of our common stock offered by this prospectus supplement and the accompanying prospectus.
March 9, 2018	10-Q	ITUS / ITUS Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2018 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporat
March 5, 2018	EX-99.1	ITUS Corporation Forms Alliance with Serametrix Corporation Exhibit 99.1 ITUS Corporation Forms Alliance with Serametrix Corporation SAN JOSE, CA – March 5, 2018: ITUS Corporation (NASDAQ: ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS’s proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix’s substantial expertise in immune monitoring assays. Serametrix flow c
March 5, 2018	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Commission
February 15, 2018	SC 13D	ITUS / ITUS Corp. / Titterton Lewis H jr - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. ) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Lewis H. Titterton Jr. 1900 Purdue A
February 14, 2018	EX-1	Exhibit 23.1 Exhibit 23.1 Table of Contents Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-8 of ITUS Corporation (the ?Company?) of our report dated January 9, 2018, relating to our audits of the Company?s consolidated financial statements as of October 31, 2017 and 2016, and for each of the years ended
February 14, 2018	S-8	Table of Contents Form S-8 As filed with the Securities and Exchange Commission on February 14, 2018 Registration No.
February 12, 2018	DEF 14A	ITUS / ITUS Corp. DEF 14A DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 ITUS Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required.
January 30, 2018	SC 13G/A	ITUS / ITUS Corp. / Eames Bruce Paul - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ITUS Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45069V203 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate the rule pur
January 30, 2018	SC 13G/A	ITUS / ITUS Corp. / Eames Bruce Paul - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 – Exit Filing)* ITUS Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45069V203 (CUSIP Number) January 9, 2018 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to designate
January 26, 2018	PRE 14A	ITUS / ITUS Corp. PRELIMINARY PROXY STATEMENT SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12 ITUS Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): x No fee required.
January 23, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2018 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (
January 9, 2018	EX-10.14	License Agreement, dated November 13, 2017, between Certainty Therapeutics, Inc. and The Wistar Institute of Anatomy and Biology. (Incorporated by reference to Exhibit 10.14 to our Form 10-K, dated January 9, 2018.) (Portions of this exhibit have been redacted pursuant to a request for confidential treatment. The redacted portions have been separately filed with the Securities and Exchange Commission.) Exhibit 10.14 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 *CONFIDENTIAL TREATMENT REQUESTED* Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” LICENSE AGREEMENT This LICENSE AGREEMENT (the “Agreement”) Is made as of the 13th day of November, 2017 (the “Effective Date”), by and between THE WIS
January 9, 2018	EX-10.15	Collaboration Agreement, dated November 17, 2017, between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (Incorporated by reference to Exhibit 10.15 to our Form 10-K, dated January 9, 2018.) (Portions of this exhibit have been redacted pursuant to a request for confidential treatment. The redacted portions have been separately filed with the Securities and Exchange Commission.) Exhibit 10.15 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 *CONFIDENTIAL TREATMENT REQUESTED* Note: Confidential treatment requested with respect to certain portions hereof denoted with “[***]” COLLABORATION AGREEMENT THIS AGREEMENT is entered into on November 17, 2017 (hereinafter “Effective Date) by and between H. Lee Moffitt Cancer Center
January 9, 2018	EX-21	SUBSIDIARIES OF ITUS CORPORATION Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostic Corporation State of Delaware Certainty Therapeutics, Inc. State of Delaware CopyTele International Ltd. British Virgin Islands Cop Exhibit 21 SUBSIDIARIES OF ITUS CORPORATION Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostic Corporation State of Delaware Certainty Therapeutics, Inc.
January 9, 2018	10-K	ITUS / ITUS Corp. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ITUS CORPORATION (Exact
January 9, 2018	EX-99.3	Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 *CONFIDENTIAL TREATMENT REQUESTED* Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” SECOND AMENDME Exhibit 99.3 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 CONFIDENTIAL TREATMENT REQUESTED Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” SECOND AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT This SECOND AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT (the “Second Amendment”) is made
December 12, 2017	8-K	Termination of a Material Definitive Agreement form 8k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (
November 22, 2017	8-K	Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)
November 17, 2017	8-K	Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)
November 17, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com
November 17, 2017	EX-10.1	ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement Exhibit 10.1 ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement November 17, 2017 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171 Ladies and Gentlemen: ITUS Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with B. Riley FBR, Inc. (the ?Agent?) as follows: 1. Issuance and Sale of Shares. The Co
November 17, 2017	424B5	ITUS CORPORATION Up to 3,000,000 Shares of Common Stock Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-220963 Prospectus Supplement (To prospectus dated October 16, 2017) ITUS CORPORATION Up to 3,000,000 Shares of Common Stock We have entered into an At Market Issuance Sales Agreement with B. Riley FBR, Inc. (?B. Riley FBR?) relating to the sale of our common stock offered by this prospectus supplement and the acc
October 24, 2017	CORRESP	ITUS / ITUS Corp. ESP S-3 Acceleration Request ITUS CORPORATION 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 October 24, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
October 13, 2017	S-3	ITUS FORM S-3 form S-3 As filed with the Securities and Exchange Commission on October 13, 2017 Registration No.
October 3, 2017	8-K	Financial Statements and Exhibits, Other Events Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C
October 3, 2017	EX-99.1	ITUS Receives Notice of NASDAQ Continued Listing Compliance Exhibit 99.1 Exhibit 99.1 ITUS Receives Notice of NASDAQ Continued Listing Compliance SAN JOSE, CA ? October 3, 2017: ITUS Corporation (NASDAQ: ITUS) today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has regained compliance with the minimum bid price requirement of The Nasdaq Stock Market as required for continu
September 29, 2017	EX-10.1	ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement Exhibit 10.1 Exhibit 10.1 ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement September 28, 2017 FBR Capital Markets & Co. 1300 North 17th Street Suite 1400 Arlington, Virginia 22209 Ladies and Gentlemen: ITUS Corporation, a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with FBR Capital Markets & Co. (?FBR?) as follows: 1.
September 29, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2017 (September 28, 2017) ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdic
September 29, 2017	424B5	Units Prospectus Supplement Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-206782 Prospectus Supplement (To prospectus dated September 14, 2015) ITUS CORPORATION Up to $3,669,043 Common Stock We have entered into an At Market Issuance Sales Agreement with FBR Capital Markets & Co. (?FBR?) relating to the sale of our common stock offered by this prospectus supplement and the accompanying
September 27, 2017	8-K	Submission of Matters to a Vote of Security Holders Form-8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)
September 13, 2017	SC 13G	ITUS / ITUS Corp. / Eames Bruce Paul - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* ITUS Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 45069V203 (CUSIP Number) March 27, 20
September 8, 2017	10-Q	ITUS / ITUS Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2017 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporation
August 24, 2017	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C
August 18, 2017	8-K	Other Events Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (C
August 8, 2017	DEF 14A	ITUS DEF 14A DEF 14A 1 def14a.htm DEF 14A SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant  Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as Permitted by Rul
July 20, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com
July 12, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Comm
June 22, 2017	SC 13D/A	ITUS / ITUS Corp. / BERMAN ROBERT ANDREW - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Robert A. Berman c/o ITUS Corporati
June 22, 2017	SC 13D/A	ITUS / ITUS Corp. / KUMAR AMIT - SCHEDULE 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Amit Kumar c/o ITUS Corporation 121
June 2, 2017	8-K	Regulation FD Disclosure, Financial Statements and Exhibits Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Comm
June 2, 2017	EX-99.1	EX-99.1 EX-99.1 2 exhibit991.htm EXHIBIT 99.1
May 26, 2017	10-Q	ITUS FORM 10-Q (Quarterly Report) Form 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2017 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer inc
May 17, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of in
May 17, 2017	EX-10.1	2. Fees; Expenses; Other Arrangements. Exhibit 10.1 Exhibit 10.1 PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 1 North Federal Highway Boca Raton, Florida 33432 May 11, 2017 Ladies and Gentlemen: This letter (this ?Agreement?) constitutes the agreement between ITUS Corporation, a Delaware corporation (the ?Company?) and Dawson James Securities, Inc. (?Dawson? or the ?Placement Agent?) pursuant to which Dawson shall serve as
May 15, 2017	424B2	Units 424B2 1 prospectus.htm FORM 424B Filed pursuant to Rule 424(b)(2) Registration Statement No. 333-206782 Prospectus Supplement (To prospectus dated September 14, 2015) ITUS CORPORATION 3,500,000 Shares of Common Stock We are offering 3,500,000 of our common stock, par value $0.01 per share, for a purchase price equal to $1.05 per share. For a description of our common stock, see the section entitle
May 11, 2017	424B2	Units Prospectus Supplement The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.
April 12, 2017	8-K	Other Events Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Co
April 6, 2017	CORRESP	ITUS ESP S-3 Acceleration Request ITUS CORPORATION 12100 Wilshire Boulevard, Suite 1275 Los Angeles, CA 90025 April 6, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
April 4, 2017	8-K	ITUS FORM 8-K (Current Report/Significant Event) Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (Com
April 4, 2017	EX-99.1	ITUS Announces Closing of Rights Offering Exhibit 99.1 Exhibit 99.1 ITUS Announces Closing of Rights Offering LOS ANGELES, CA ? April 4, 2017: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), announced that its rights offering of common shares closed today, raising gross proceeds of approximately $4.7 million before payment of dealer manager fee and other expenses, through the issuance of 1,989,207 shares of common stock. Robert Berman, ITUS?s P
March 31, 2017	S-3	ITUS FORM S-3 S-3 As filed with the Securities and Exchange Commission on March 31, 2017 Registration No.
March 31, 2017	EX-99.1	AGREEMENT Exhibit 99.1 Exhibit 99.1 AGREEMENT This agreement ("Agreement") is entered into this 11 day of November, 2013 (the "Effective Date"), by and between Meetrix Communications, Inc. ("Assignor"), a corporation with an address at c/o AVG Ventures 500 Ygnacio Valley road, Suite 360 Walnut Creek, CA 94596, and CTI PATENT ACQUISITION CORPORATION ("CTIPAC"), a Delaware corporation, having a principal plac
March 24, 2017	RW	ITUS REQUEST WITHDRAWAL OF S-1 FILE NO. 333-215799 Form RW ITUS CORPORATION 12100 Wilshire Boulevard, Suite 1275 Los Angeles, CA 90025 March 24, 2017 VIA EDGAR Securities and Exchange Commission 100 F.
March 15, 2017	10-Q	ITUS FORM 10-Q (Quarterly Report) Form 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2017 Commission file number 0-11254 ITUS Corporation (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer i
March 8, 2017	EX-10.1	1. The Rights Offering. Exhibit 10.1 Exhibit 10.1 DEALER-MANAGER AGREEMENT March 3, 2017 Advisory Group Equity Services, Ltd. doing business as RHK Capital As Dealer-Manager 444 Washington Street, Suite 407 Woburn, Massachusetts 01801 Ladies and Gentlemen: The following will confirm our agreement relating to the proposed subscription rights offering (the ?Rights Offering?) to be undertaken by ITUS Corporation, a Delaware
March 8, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 form8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of i
March 6, 2017	424B2	QUESTIONS AND ANSWERS RELATING TO THE RIGHTS OFFERING THE RIGHTS OFFERING MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES PLAN OF DISTRIBUTION Units 424B2 1 prospectus.htm FORM 424B Filed pursuant to Rule 424(b)(2) Registration Statement No. 333-206782 Prospectus Supplement (To prospectus dated September 14, 2015) ITUS CORPORATION 9,066,987 Subscription Rights to Purchase Shares of Common Stock and Up to 3,703,703 Shares of Common Stock Issuable upon Exercise of Subscription Rights We are distributing to the holders of our common stock and cer
February 14, 2017	8-K	ITUS FORM 8-K (Current Report/Significant Event) form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)
February 14, 2017	EX-99.1	ITUS Extends Ownership Period and Changes Record Date for Stock Rights Offering Exhibit 99.1 Exhibit 99.1 ITUS Extends Ownership Period and Changes Record Date for Stock Rights Offering LOS ANGELES, CA ? February 10, 2017: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), a company using the power of the immune system for early cancer detection, is changing the Record Date for its current stock rights offering. The new Record Date will be Wednesday March 1, 2017. For new shareholders
January 27, 2017	S-1	Meetrix will experience immediate and substantial dilution as a result of this issuance. As filed with the Securities and Exchange Commission on January 27, 2017 Registration No.
January 19, 2017	EX-99.1	ITUS Announces Common Stock Rights Offering and Ownership Day Exhibit 99.1 ITUS Announces Common Stock Rights Offering and Ownership Day LOS ANGELES, CA ? January 19, 2017: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), a company developing Cchek?, a cancer diagnostic platform based on the body?s immunological response to a malignancy, today announced that its board of directors has approved a rights offering for ITUS shareholders of up to $12,000,000. The rights
January 19, 2017	8-K	ITUS FORM 8-K (Current Report/Significant Event) form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2017 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (
January 3, 2017	SC 13G	ITUS / ITUS Corp. / Titterton Lewis H jr - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (Amendment No. ) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
December 8, 2016	10-K/A	ITUS FORM 10-K/A (Annual Report) form10K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Amendment No. 1) [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11
December 7, 2016	8-K	ITUS FORM 8-K (Current Report/Significant Event) form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation) (
December 7, 2016	EX-99.1	ITUS Announces CchekÔ Preliminary Cancer Patient Efficacy Study Results Exhibit 99.1 Exhibit 99.1 ITUS Announces Cchek? Preliminary Cancer Patient Efficacy Study Results LOS ANGELES, CA ? December 7, 2016: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), today announced preliminary results from its Cchek? cancer patient efficacy study. Using its most recent protocols and methods for measuring a patient?s immunological response to a malignancy, the Company achieved Sensitivit
December 7, 2016	10-K	ITUS FORM 10-K (Annual Report) form10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K [x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2016 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11254 ITUS CORPORATION
December 7, 2016	EX-4.2	Form of Warrant issued to Adaptive Capital LLC. (Incorporated by reference to Exhibit 4.2 to our Form 10-K, dated December 7, 2016.). Exhibit 4.2 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE OFFERED FOR SALE, SOLD,ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED OR OTHERWISE DISPOSED OF (I) IN THE ABSENCE OF (A)
December 7, 2016	EX-10.21	Letter Agreement, dated October 17, 2016, between the Company and Mike Catelani. (Incorporated by reference to Exhibit 10.21 to our Form 10-K, dated December 7, 2016.) Exhibit 10.21 ITUS CORPORATION October 17, 2016 Mr. Mike Catelani Re: Employment - CFO Position ITUS Corporation Dear Mike: We are pleased to extend you an offer for full time employment at ITUS Corporation (the "Company") as Chief Financial Officer. As we discussed, our current CFO is on part time status, and will be retiring on December 31, 2016. We would like you to join the Company as of Novem
December 7, 2016	EX-10.20	ITUS CORPORATION 12% Secured Debenture Due November 11, 2017 Exhibit 10.20 ITUS CORPORATION 12% Secured Debenture Due November 11, 2017 $3,000,000 ITUS Corporation., a Delaware corporation (the “Company” or “Maker”), for value received, hereby promises to pay to Adaptive Capital LLC or its registered assigns (the “Payee” or “Holder”), at 500 Ygnacio Valley Road, Suite 360 Walnut Creek, CA 94596 upon due presentation and surrender of this twelve percent (12%
December 7, 2016	EX-99.1	Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 *CONFIDENTIAL TREATMENT REQUESTED* Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” COLLABORATIVE Exhibit 99.1 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 CONFIDENTIAL TREATMENT REQUESTED Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” COLLABORATIVE RESEARCH AGREEMENT This COLLABORATIVE RESEARCH AGREEMENT (the “Agreement”) is made as of the 14th day of July, 2015 (the “Effective Date”
December 7, 2016	EX-10.19	LETTER AGREEMENT Exhibit 10.19 LETTER AGREEMENT This Letter Agreement (the “Agreement”) is entered into by and between ITUS Corporation, a Delaware corporation (the “Company”), and Adaptive Capital LLC (“Adaptive”). WHEREAS, Adaptive is the holder of 3,500 shares of Series A Convertible Preferred Stock (the “Preferred Stock”) representing all of the issued and outstanding shares of preferred stock of the Company;
December 7, 2016	EX-21	SUBSIDIARIES OF ITUS CORPORATION Exhibit 21 SUBSIDIARIES OF ITUS CORPORATION Name of Company and Name Doing Business Jurisdiction of Organization Anixa Diagnostics Corporation Sate of Delaware CopyTele International Ltd.
December 7, 2016	EX-99.1	Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 *CONFIDENTIAL TREATMENT REQUESTED* Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” COLLABORATIVE Exhibit 99.3 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 CONFIDENTIAL TREATMENT REQUESTED Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” COLLABORATIVE RESEARCH AGREEMENT This COLLABORATIVE RESEARCH AGREEMENT (the “Agreement”) is made as of the 4th day of August, 2016 (the “Effective Date
December 7, 2016	EX-99.2	Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 *CONFIDENTIAL TREATMENT REQUESTED* Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” FIRST AMENDMEN Exhibit 99.2 Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11-2622630 CONFIDENTIAL TREATMENT REQUESTED Note: Confidential treatment requested with respect to certain portions hereof denoted with “[*]” FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT This FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AGREEMENT (the “First Amendment”) is made as
November 9, 2016	SC 13D/A	ITUS / ITUS Corp. / Titterton Lewis H jr - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE IN INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3) ITUS CORPORATION (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 45069V203 (CUSIP Number) Lewis H. Titterton Jr. 1900 Purdy A
October 21, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)
October 18, 2016	EX-99.1	ITUS Receives Notice of NASDAQ Continued Listing Compliance Exhibit 99.1 Exhibit 99.1 ITUS Receives Notice of NASDAQ Continued Listing Compliance LOS ANGELES, CA ? October 17, 2016: ITUS Corporation (?ITUS?) (NASDAQ: ITUS), today announced that it has received formal notice from the Listing Qualifications Staff of The NASDAQ Stock Market LLC that the company has evidenced compliance with all requirements for continued listing on The Nasdaq Capital Market.
October 18, 2016	8-K	ITUS FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdiction of incorporation)
August 26, 2016	8-K	ITUS FORM 8-K (Current Report/Significant Event) FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2016 ITUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-11254 11-2622630 (State or other jurisdictionof incorporation) (C

ANIX / Anixa Biosciences, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings